Author:
Ribich Scott,Harvey Darren,Copeland Robert A.
Subject
Clinical Biochemistry,Drug Discovery,Pharmacology,Molecular Biology,Molecular Medicine,Biochemistry
Reference122 articles.
1. Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study;Amorim;Lancet Haematol.,2016
2. Modulation of epigenetic targets for anticancer therapy: clinicopathological relevance, structural data and drug discovery perspectives;Andreoli;Curr. Pharm. Des.,2013
3. Epigenetic protein families: a new frontier for drug discovery;Arrowsmith;Nat. Rev. Drug Discov.,2012
4. A novel histone deacetylase 8 (HDAC8)-specific inhibitor PCI-34051 induces apoptosis in T-cell lymphomas;Balasubramanian;Leukemia,2008
5. Conformational adaptation drives potent, selective and durable inhibition of the human protein methyltransferase DOT1L;Basavapathruni;Chem. Biol. Drug Des.,2012
Cited by
48 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献